People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| eGenesis, Inc. | — | Biotechnology | Series D+ | $265.0M | $316.4M | 2019 |
| Variant Bio, Inc. | — | Biotechnology | Series D+ | $127.7M | $2.8B | 2020 |
| Kelonia Therapeutics, Inc. | — | Biotechnology | Series C | $50.3M | $1.0B | 2022 |
| Nuon Therapeutics Inc | — | Biotechnology | Series A | $29.7M | $361.5M | 2009 |
| Hunger Not Impossible, Inc. | — | Other | Series A | $15.2M | $20.8M | 2020 |
| Ally Therapeutics, Inc. | — | Pharmaceuticals | Series A | $10.0M | $309.7M | 2019 |
Bob More at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bob More on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Julie Sunderland | 2 | 5 |
| Steven Gillis | 1 | 23 |
| Bryan Roberts | 1 | 18 |
| Steve Gillis | 1 | 13 |
| Adam Goulburn | 1 | 10 |
| Stuart Nagae | 1 | 9 |
| Josh Wolfe | 1 | 8 |
| Robert More | 1 | 7 |
| PAUL SEKHRI | 1 | 7 |
| Brad Smith | 1 | 6 |
| Kim Kamdar | 1 | 6 |
| Lucio Iannone | 1 | 6 |
| David Cordo | 1 | 6 |
| Arlene Morris | 1 | 5 |
| Geoff MacKay | 1 | 5 |
| Isaac Ciechanover | 1 | 5 |
| Elena Viboch | 1 | 4 |
| Ken Denman | 1 | 3 |
| Joshua Funder | 1 | 3 |
| Boris Nikolic | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.